W
WAVEMAN · COMPANY
SXTP · 60 Degrees Pharmaceuticals, Inc.
> Ask across nine datasets ⌘K
LIVE
TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475
← ALL COMPANIES

SXTP

60 DEGREES PHARMACEUTICALS, INC.
PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001946563
C-SUITE BUYING · 1☆ WATCH
INSIDER NET · 180D
$10.1K
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
1
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
0
13F, latest reported quarter
REVENUE GROWTH
+65.5%
XBRL, annual
NET MARGIN
-732.5%
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net +$10.1K over 180 days
+$10.1K over 90 days
more than 68% of Pharma & Biotech
CONGRESS
no member of Congress has reported trading it
FUNDS
fewer than five institutions report holding it
REVENUE
+65.5% year over year
more than 82% of Pharma & Biotech
MARGIN
-732.5% net margin
below 85% of Pharma & Biotech
BUYBACKS
no share repurchases reported
SHORT
no short interest reported
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN -83.8%
-83.8%12M
-84%-47%-10%+27%2025-092025-102025-122026-032026-052026-072026-09 2026-06-12 · DOW GEOFFREY S bought $10.1K2025-12-10 · DOW GEOFFREY S bought $8.9K2025-12-15 · DOW GEOFFREY S bought $7.7K2025-12-11 · DOW GEOFFREY S bought $3.3K
INSIDER BUY
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
Insiders are net buyers of their own stock.
The record shows a net $10.1K bought by insiders over 180 days. Every figure is a federal filing, dated the day it became public.
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, 60 DEGREES PHARMACEUTICALS, INC. insiders bought a net $10.1K of stock across 22 Form 4 purchases and sales, with 1 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER
FILED
SHARES
VALUE
DOW GEOFFREY S
President and CEO
BUY
2026-06-12
7,350.0
$10.1K
DOW GEOFFREY S
President and CEO
BUY
2025-12-15
9,670.0
$7.7K
DOW GEOFFREY S
President and CEO
BUY
2025-12-11
3,613.0
$3.3K
DOW GEOFFREY S
President and CEO
BUY
2025-12-10
9,350.0
$8.9K
XU CHERYL
Director
BUY
2025-06-03
2,000.0
$5.8K
22 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 17 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported

no 13F holders found for this ticker

SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
FORM 144
No planned-sale notices
No insider has notified an intent to sell. This is the panel to watch after a run-up.
Clinical pipeline
ClinicalTrials.gov · 5 registered trials, 2 still enrolling or running — a status change here is dated weeks before the press release
4
Phase 2
2 ACTIVE
1
Not applicable
0 ACTIVE
TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122022-12
REVENUE$1.0M$607.6K$253.6K$223.2K
GROSS PROFIT$223.8K$222.8K$-221.0K$-209.2K
OPERATING INCOME$-7.8M$-9.7M$-5.2M$-1.8M
NET INCOME$-7.4M$-7.9M$-3.8M$-6.2M
EPS (DILUTED)-11.73-74.17-59.18-2.61
OPERATING CASH FLOW$-6.8M$-5.6M$-4.5M$-1.0M
CASH$1.5M$1.7M$2.1M
LONG-TERM DEBT$144.0K$147.1K$150.0K
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-06 ALL SYSTEMS LIVE FOR MACHINES →